Literature DB >> 2375945

Effects of the acute administration of caffeine in patients with schizophrenia.

P B Lucas1, D Pickar, J Kelsoe, M Rapaport, C Pato, D Hommer.   

Abstract

Caffeine, 10 mg/kg, was administered to 13 schizophrenic patients in a double-blind placebo-controlled study of its behavioral effects. Some measures of psychopathology were significantly increased: Brief Psychiatric Rating Scale (BPRS) total, BPRS subscales thought disorder, unusual thought content, and euphoria-activation, and several individual BPRS items. Nurses' Bunney-Hamberg ratings of psychosis and mania, comparing the day before with the day after pharmacological challenge, increased significantly. Compared to placebo, caffeine also produced significant increases of diastolic blood pressure and cortisol. Thus, these findings indicate that caffeine increases arousal and has a psychotogenic effect when administered to schizophrenic patients. The possible roles of various neurotransmitters is discussed with special emphasis on caffeine's actions on dopaminergic and adenosinergic systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2375945     DOI: 10.1016/0006-3223(90)90429-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

1.  Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia.

Authors:  C-J Hong; H-C Liu; T-Y Liu; D-L Liao; S-J Tsai
Journal:  J Neural Transm (Vienna)       Date:  2005-02-22       Impact factor: 3.575

2.  Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain.

Authors:  Kelly Juliana Seibt; Renata da Luz Oliveira; Mauricio Reis Bogo; Mario Roberto Senger; Carla Denise Bonan
Journal:  Fish Physiol Biochem       Date:  2015-07-09       Impact factor: 2.794

3.  Schizophrenia: Nutrition and Alternative Treatment Approaches.

Authors:  Berenice Royal
Journal:  Schizophr Bull       Date:  2015-01-22       Impact factor: 9.306

4.  Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.

Authors:  Jie Zhang; Chadi G Abdallah; Junqing Wang; Xiaona Wan; Chunlian Liang; Liyun Jiang; Yuzhen Liu; Haixing Huang; Xiaohong Hong; Qingjun Huang; Renhua Wu; Chongtao Xu
Journal:  Psychiatry Res       Date:  2012-06-16       Impact factor: 3.222

5.  Higher serum caffeine in smokers with schizophrenia compared to smoking controls.

Authors:  Kunal K Gandhi; Jill M Williams; Matthew Menza; Magdalena Galazyn; Neal L Benowitz
Journal:  Drug Alcohol Depend       Date:  2010-03-12       Impact factor: 4.492

6.  Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake.

Authors:  Susana Mingote; Mariana Pereira; Andrew M Farrar; Peter J McLaughlin; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2008-01-17       Impact factor: 3.533

7.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis".

Authors:  Elisabet Aliagas; Izaskun Villar-Menéndez; Jean Sévigny; Mercedes Roca; Miriam Romeu; Isidre Ferrer; Mireia Martín-Satué; Marta Barrachina
Journal:  Purinergic Signal       Date:  2013-06-16       Impact factor: 3.765

Review 9.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice.

Authors:  Sylvain Dubroqua; Benjamin K Yee; Philipp Singer
Journal:  Psychopharmacology (Berl)       Date:  2014-04-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.